Ambrx Biopharma Inc

Ambrx Biopharma Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ambrx Biopharma, Inc. is a clinical-stage biologics company, which engages in discovering and developing a novel class of engineered precision biologics (EPBs). Using its proprietary expanded genetic code technology platform, it allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, and ARX305. The company was founded on August 11, 2023 and is headquartered in La Jolla, CA.

SAN DIEGO, July 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ambrx's proprietary anti-PSMA antibody-drug conjugate (ADC) investigational therapy, ARX517, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) upon progression on an androgen receptor pathway inhibitor. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs which may demonstrate substantial improvement over available therapy for serious conditions with unmet medical need.

FDA Grants Fast Track Designation for Ambrx's ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced the closing of its previously announced market-priced registered direct offering of approximately $75 million (the “Offering”) of its American Depositary Shares of the Company (“ADS”) at a price of $13.93 per ADS. The Offering was priced based on the 5-day trailing VWAP for the ADS on the effective date of the purchase agreement related to the Offering.

Ambrx Announces Closing of $75 Million Market Priced Registered Offering

SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced the appointment of Jared Kelly as Senior Vice President, General Counsel and Corporate Secretary. After practicing for more than ten years at large corporate law firms, Mr. Kelly brings his extensive experience advising public companies on corporate governance, financing transactions and mergers and acquisitions to Ambrx. He will be responsible for developing and overseeing the legal strategy of the Company and for providing legal guidance to the Company's board of directors, executive management team and other business units.

Ambrx Appoints Jared Kelly as General Counsel

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview at the TD Cowen Oncology Innovation Summit, the Jefferies Healthcare Conference, and the Goldman Sachs 44th Annual Global Healthcare Conference in the coming weeks. The presentations will focus on the status of Ambrx's clinical development strategy and an update on the progress of its lead clinical candidates, ARX788 and ARX517.

Ambrx to Present at Multiple Upcoming Investor Meetings

SAN DIEGO, May 24, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that it has entered into a securities purchase agreement with clients managed by Darwin Global Management Ltd. (“Darwin”) for the sale of an aggregate of approximately 5.4 million American Depositary Shares of the Company (“ADS”) at a price of $13.93 per ADS, which is based on the 5-day trailing VWAP for the ADS, pursuant to a registered direct offering (the “offering”). In connection with the offering, Darwin has agreed not to sell any of the Company's securities it holds for a period of six months following the closing of the offering.

Ambrx Announces $75 Million Market Priced Registered Offering

Ambrx Biopharma's stock value has surged due to positive preliminary data from cancer-targeting clinical trials of ARX788 and ARX517. With cash reserves increasing to $149.6 million in Q1 2023, Ambrx can continue developing its innovative cancer treatments.

Ambrx Biopharma: ARX788's Potential In Cancer Treatment Presents Promising Opportunity

Ambrx's lead therapies target breast cancer and prostate cancer, two of the most common forms of cancer. The company has enough cash, it said, to fund operations for another year.

Why Shares of Ambrx Biopharma Jumped This Week

SAN DIEGO, May 18, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced that Stephen Glover has joined the Company's Board of Directors as Chairman. Mr. Glover has extensive experience building successful biopharmaceutical companies, with a focus on pharmaceutical business strategy, corporate development, product development, commercialization, and business optimization. The Company's former Chair, Katrin Rupalla, Ph.D., has resigned from Ambrx's Board of Directors to pursue another opportunity, which precludes her ability to serve on any boards of directors.

Ambrx Appoints Stephen Glover as Chairman of its Board of Directors

Ambrx Biopharma Inc. is up 40x since February after posting positive clinical data. However, that sort of rally makes a stock unstable.

Ambrx Biopharma: Very Strong Rally On Positive Data, But Unstable Price

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview at the JMP Securities Life Sciences Conference and RBC Capital Markets Global Healthcare Conference taking place in New York City on May 16th and 17th, respectively. The presentations will focus on the status of Ambrx's clinical development strategy and an update on the progress of its lead clinical candidates, ARX788 and ARX517.

Ambrx to Present at JMP Securities Life Sciences and RBC Capital Markets Global Healthcare Conferences

Three posters will be presented at AACR and include data from preclinical studies of ARX517 and ARX305 and Trial in Progress Poster on APEX-01 Three posters will be presented at AACR and include data from preclinical studies of ARX517 and ARX305 and Trial in Progress Poster on APEX-01

Ambrx to Present Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual Meeting

Atlas Technical Consultants

Fulcrum Therapeutics Inc

Genelux Corp

Canoo

LanzaTech Global Inc

NGL Energy Partners

Nektar Therapeutics

FiscalNote Holdings Inc

SelectQuote

Small-cap stocks, in general, are more domestic in nature, and this protects them from geopolitical and foreign exchange risks.

5 Best and Worst Performing Small-Cap Stocks in February 2023

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), today announced that it has completed net sales of approximately $78 million of American Depositary Shares (“ADSs”) pursuant to the Company's at-the-market (“ATM”) program established on Aug 5, 2022, through Cowen and Company LLC (“TD Cowen”), acting as sales agent. The ATM program had an aggregate offering price of up to $80 million in gross proceeds.

Ambrx Raises $78 Million and Completes its ATM Program

Fintel reports that Darwin Global Management has filed a 13D form with the SEC disclosing ownership of 79.13MM shares of Ambrx Biopharma Inc.

Darwin Global Management Now Owns 26.4% of Ambrx Biopharma

Ambrx is a clinical-stage biotech and is not profitable. The company's lead therapy is ARX788, which is being tested as an add-on therapy to treat breast cancer.

Why Shares of Ambrx Biopharma Fell Tuesday

Analysts have recently rated Ambrx Biopharma, Inc (NYSE: AMAM) a Moderate Buy, even though its $8.50 price target represents a 33% downside. While its current $12.54 share price–and $390.06 million in market capitalization–are certainly attractive enough to investors at all levels, the forecast slip might deter more cautious players.

Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc. (NYSE: AMAM) (“Ambrx” or “the Company”) today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange, effective March 16, 2023 after market close. Ambrx's American Depositary Shares are expected to begin trading as a Nasdaq-listed security on March 17, 2023. The Company will retain its current ticker symbol “AMAM”.

Ambrx to Commence Trading on Nasdaq

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM) announced today that it has been informed by its partner, NovoCodex Biopharmaceuticals, Inc.

ACE-Breast-02 Pivotal Phase 3 Study of Ambrx's ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results

Faraday Future Intelligent Electric

Sorrento Therapeutics Inc

Troika Media Group

Use these tips for staying disciplined when it comes to investing in penny stocks The post How to Stay Disciplined When Investing in Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Stay Disciplined When Investing in Penny Stocks

Ambrx Biopharma (NYSE: AMAM ) stock is falling on Friday but it's not due to any news released by the company today. Instead, it looks like shares are retreating from a rally on Thursday.

Why Is Ambrx Biopharma (AMAM) Stock Down 15% Today?

NexImmune

Use these tips for identifying penny stocks trends in 2023 The post How to Identify Trends With Penny Stocks in 2023  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Identify Trends With Penny Stocks in 2023

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM) today announced encouraging initial data from its ongoing Phase 1 trial (APEX-01 (NCT04662580)) investigating ARX517, Ambrx's proprietary anti-PSMA ADC, in prostate cancer patients. APEX-01 is a Phase 1, first-in-human, open label dose escalation and dose expansion trial enrolling patients with advanced prostate cancer whose tumors have progressed on at least two prior FDA-approved treatments.

ARX517, Ambrx's Proprietary Anti-PSMA ADC, Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody drug conjugates (ADCs), today announced that it will host a virtual analyst and investor day on February 24 from 12:00pm – 1:00pm ET. The event will feature discussions from oncology experts Hope S. Rugo, M.D.

Ambrx Biopharma to Host Analyst and Investor Day to Discuss ARX788 in Breast Cancer and ARX517 in Prostate Cancer

SAN DIEGO--( BUSINESS WIRE )--Ambrx Biopharma, Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody-drug conjugates (ADCs), has appointed Sandra Aung, Ph.D., as Executive Vice President, Head of Clinical Development. Dr. Aung will assume all clinical development leadership responsibilities of Ambrx's proprietary pipeline of several ADC product candidates.

Ambrx Biopharma Strengthens Clinical Leadership with Appointment of Sandra Aung, Ph.D. as Head of Clinical Development

Biora Therapeutics Inc

Luminar Technologies

Short squeeze stocks to watch. The post Penny Stocks To Buy?

News for Ambrx Biopharma Inc Stock (AMAM)